Allergy Asthma and Clinical Immunology最新文献

{"title":"Association of myeloid cell reactivity patterns with safe food predictions in FPIES patients.","authors":"Georgiana M Sanders, Alexandra Hua, Elizabeth Hudson, Jonathan P Troost, Nobuhiko Kamada, John Y Kao, Charles F Schuler, Mohamad El-Zaatari","doi":"10.1186/s13223-025-00968-1","DOIUrl":"10.1186/s13223-025-00968-1","url":null,"abstract":"<p><strong>Background: </strong>Food protein-induced enterocolitis syndrome (FPIES) is an understudied non-IgE-mediated food allergy, which is distinct from and lacks diagnostic testing akin to IgE testing. FPIES affects infants and toddlers but can persist into adulthood. As there are no extant methods to identify safe foods for FPIES patients, food ingestion trials are performed at home and often lead to reactions and development of food aversions, which may lead to failure-to-thrive and gastric feeding tube requirements. We hypothesized that foods that fail to elicit responses in immune cells of FPIES patients would be safe to ingest, which could support development of a diagnostic method to headstart safe food identification in patients.</p><p><strong>Methods: </strong>We developed an ex vivo model of FPIES using food-stimulated white blood cells (WBCs) from pediatric FPIES patients and controls by defining a 9-gene panel representative of FPIES ex vivo responses and conducted a single-arm pilot clinical trial.</p><p><strong>Results: </strong>Myeloid cells of FPIES patients displayed variable individual-specific myeloid cell reactivity patterns (iMCRPs) to different foods. Foods that failed to elicit repsonses in patients' immune cells were safe to ingest with a negative predictive value of 98.5%. This, when utilized in prospective predictions, reduced newly introduced food reaction rates from 19.5 to 0% while increasing food repertoire diversity.</p><p><strong>Conclusions: </strong>iMCRPs represent a novel and potentially useful tool that associates with safe food ingestion in FPIES patients for foods that fail to elicit immune cell reactions. Trial Registration The trial has been registered at registered at ClinicalTrials.gov # NCT04644783.</p>","PeriodicalId":51302,"journal":{"name":"Allergy Asthma and Clinical Immunology","volume":"21 1","pages":"24"},"PeriodicalIF":2.4,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12093898/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144121376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Benralizumab for acute thromboembolism in hypereosinophilic syndrome: a case report.","authors":"Daiki Nagira, Satoshi Miyamoto, Taishiro Mizukoshi, Atsushi Yanagisawa, Atsushi Funauchi, Kensuke Kanaoka, Hanako Yoshimura, Tatsunori Jo, Masayoshi Higashiguchi, Yujiro Naito, Takayuki Shiroyama, Satoshi Tetsumoto, Haruhiko Hirata, Yoshito Takeda, Atsushi Kumanogoh","doi":"10.1186/s13223-025-00967-2","DOIUrl":"10.1186/s13223-025-00967-2","url":null,"abstract":"<p><strong>Background: </strong>Hypereosinophilic syndrome is a group of disorders characterized by organ dysfunction caused by hypereosinophilia, which frequently leads to thromboembolic complications with potentially fatal outcomes. Interleukin-5, a key cytokine that promotes the differentiation and activation of eosinophils, has been identified as a therapeutic target. Anti-interleukin-5 antibody therapy has demonstrated efficacy in reducing eosinophil counts and enabling steroid dose tapering in patients with hypereosinophilic syndrome. This report describes the case of a patient with severe thromboembolism associated with hypereosinophilic syndrome during the acute phase who was successfully treated with benralizumab, an anti-interleukin-5 receptor alpha antibody.</p><p><strong>Case presentation: </strong>A 22-year-old woman presented with a persistent cough and was diagnosed with eosinophilic pneumonia and portal vein thrombosis. Although eosinophilic pneumonia improved with corticosteroid therapy, thrombotic complications worsened despite additional anticoagulant treatment. The administration of benralizumab led to marked improvement in thrombosis, resulting in clinical recovery.</p><p><strong>Conclusions: </strong>This case suggests that the early administration of anti-interleukin-5 receptor antibody therapy may be a valuable treatment option for refractory thrombosis.</p>","PeriodicalId":51302,"journal":{"name":"Allergy Asthma and Clinical Immunology","volume":"21 1","pages":"23"},"PeriodicalIF":2.6,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12085812/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144095586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perflutren lipid microspheres for echocardiogram contrast: a clinical case of anaphylaxis not caused by PEG.","authors":"Chloe Wang, Jackie Campbell, Harriet Lea-Banks, Erika Lee","doi":"10.1186/s13223-025-00964-5","DOIUrl":"https://doi.org/10.1186/s13223-025-00964-5","url":null,"abstract":"<p><strong>Background: </strong>Perflutren lipid microsphere suspension, sold under the brand name Definity®, is a microbubble ultrasound contrast agent. The microspheres contain octafluoropropane (C₃F₈) gas encapsulated by an outer lipid shell of phospholipids and a polyethylene glycol (PEG)ylated phospholipid. Anaphylaxis to perflutren lipid microsphere is very rare, with only one case report clearly attributing the reaction to the PEG excipient. We report a novel case of anaphylaxis likely caused by a non-PEGylated component of Definity®.</p><p><strong>Case presentation: </strong>Our patient is a healthy 54-year-old female, who underwent an exercise stress transthoracic echocardiogram using Definity® as an enhancing agent. She experienced anaphylaxis within 15 min of injection. Symptoms resolved after she was treated with diphenhydramine and epinephrine, followed by a systemic corticosteroid and ondansetron in the Emergency Department. The patient underwent allergy testing at our clinic for Definity® and various PEG-containing substances. While all PEG products tested negative, she had positive intradermal tests to Definity®. She also had negative skin prick testing to PEG 8000 and passed an oral challenge to PEG 3350, thus ruling out PEG as the causative agent of anaphylaxis.</p><p><strong>Conclusions: </strong>Our case report highlights a previously undocumented instance of anaphylaxis to Definity® not caused by PEG. We suspect the reaction to be an IgE-mediated response to a non-PEGylated component of Definity®. An alternative explanation for the reaction could be a complement activation-related pseudoallergy. This report provides critical information to physicians on the potential risks of using Definity® and contributes to growing research surrounding the profile of Definity®.</p>","PeriodicalId":51302,"journal":{"name":"Allergy Asthma and Clinical Immunology","volume":"21 1","pages":"22"},"PeriodicalIF":2.6,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12060560/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144052718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pitaya allergy: a case report of anaphylaxis in a patient without cross-reactive allergens.","authors":"Hannah Martin, Peter Stepaniuk","doi":"10.1186/s13223-025-00962-7","DOIUrl":"https://doi.org/10.1186/s13223-025-00962-7","url":null,"abstract":"<p><strong>Background: </strong>Pitaya, commonly known as dragon fruit, is increasingly available and has allergenic potential. Pollens have been found to have cross-reactivity and thus induce allergies to several fruits, however, to our knowledge this is first report of pitaya anaphylaxis in a patient without co-sensitization to other fruit or environmental allergens.</p><p><strong>Case presentation: </strong>A 26-year-old male presented to the emergency department with anaphylaxis after consumption of pitaya (dragon fruit). He had no prior history of atopy. Epicutaneous skin testing demonstrated positive to pitaya and negative to all other cross-reactive food and environmental allergens, suggesting his pitaya allergy did not derive from cross-sensitization.</p><p><strong>Conclusions: </strong>Our case is unique in demonstrating the potential for pitaya allergy to occur independent of other allergies and cross-sensitization. Future research is warranted into suspected allergenic proteins in pitaya and quantifying their structural similarity to other known allergens.</p>","PeriodicalId":51302,"journal":{"name":"Allergy Asthma and Clinical Immunology","volume":"21 1","pages":"21"},"PeriodicalIF":2.6,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12054184/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144055352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dermatologic presentations of hyper IgE syndrome in pediatric patients.","authors":"Mohammad Mahjoubi, Ronak Rashedi, Noosha Samieefar, Fahimeh Abdollahimajd, Nima Rezaei","doi":"10.1186/s13223-025-00963-6","DOIUrl":"https://doi.org/10.1186/s13223-025-00963-6","url":null,"abstract":"<p><strong>Background: </strong>Hyper-IgE Syndrome, also known as Job's syndrome, is a rare primary immunodeficiency disorder characterized by recurrent infections and elevated levels of immunoglobulin E. While respiratory and systemic manifestations have been more emphasized, dermatological manifestations in Hyper-IgE Syndrome also play a significant role in disease presentation.</p><p><strong>Methods: </strong>This narrative review explores the dermatologic presentations of Hyper-IgE Syndrome in pediatric populations, including descriptions, associated symptoms/findings, and available treatment options.</p><p><strong>Results and conclusion: </strong>Neonatal rash, mucocutaneous candidiasis, noma neonatorum, psoriasis, cold staphylococcal abscesses, and candida onychomycosis are among the dermatological manifestations of Hyper-IgE Syndrome. Each manifestation has unique characteristics and treatment considerations, necessitating accurate recognition and diagnosis for effective management. Optimal treatment strategies involve a combination of supportive care, topical/systemic therapies, antifungal medications, and surgical interventions when necessary. Further research is needed to enhance our understanding of these manifestations and evaluate treatment modalities for individuals affected by Hyper-IgE Syndrome.</p>","PeriodicalId":51302,"journal":{"name":"Allergy Asthma and Clinical Immunology","volume":"21 1","pages":"20"},"PeriodicalIF":2.6,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12049024/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144055348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Late presentation of X-linked inhibitor of apoptosis (XIAP) deficiency in a young adult.","authors":"Samina Nazarali, Beata Derfalvi, Pascale Clark","doi":"10.1186/s13223-025-00965-4","DOIUrl":"https://doi.org/10.1186/s13223-025-00965-4","url":null,"abstract":"<p><strong>Background: </strong>X-linked inhibitor of apoptosis (XIAP) deficiency is a rare inborn error of immunity which occurs secondary to mutations in the XIAP/BIRC4 gene. Disease onset usually manifests within the first few years of life, and is associated with a spectrum of clinical features, secondary to immune dysregulation. Males typically present with refractory chronic colitis, hemophagocytic lymphohistiocytosis, and severe and/or recurrent infections. Laboratory analysis may reveal hypogammaglobulinemia and cytopenias. At present, the only curative treatment is allogenic hematopoietic stem cell transplantation.</p><p><strong>Case presentation: </strong>A 24-year-old gentleman, immigrant from the Democratic Republic of Congo, was referred to outpatient immunology for evaluation of an inborn error of immunity given a past medical history significant for refractory fistulizing Crohn's disease, arthritis, liver abscesses, prior disseminated tuberculosis, anemia, and recurrent infections. He had been asymptomatic throughout his childhood and adolescence, with no infections or symptoms of inflammatory disease until the age of 19, when he was diagnosed with Crohn's disease. He was soon after admitted to hospital and was diagnosed with hemophagocytic lymphohistiocytosis. Primary immunodeficiency gene panel testing revealed a nonsense variant XIAP c833C > G p.(Ser278*), which generates a premature stop codon at exon 2 (of total 7 exons). On flow cytometry analysis, XIAP protein expression was significantly reduced, confirming the diagnosis of XIAP deficiency.</p><p><strong>Conclusion: </strong>This is one of the only documented reports of a patient with XIAP deficiency, presenting with symptom-onset in adulthood. This case highlights the need to maintain a high index of suspicion for XIAP deficiency in patients with the appropriate clinical presentation, despite advanced age of presentation.</p>","PeriodicalId":51302,"journal":{"name":"Allergy Asthma and Clinical Immunology","volume":"21 1","pages":"19"},"PeriodicalIF":2.6,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12042373/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144065196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful dupilumab treatment in a patient with severe dermatitis following allogenic hematopoietic stem cell transplantation.","authors":"Young-Hee Nam, Hyun Jung Jin","doi":"10.1186/s13223-025-00966-3","DOIUrl":"https://doi.org/10.1186/s13223-025-00966-3","url":null,"abstract":"<p><strong>Background: </strong>Allogenic hematopoietic stem cell transplantation (HSCT) is the optimal treatment of hematologic diseases and various malignancies. Development of allergic disease in a transplant patient has been reported.</p><p><strong>Case presentations: </strong>A 49-year-old male with no history of atopy underwent two allogenic HSCTs for aplastic anemia from his brother with severe atopic dermatitis 11 years ago. The patient developed eczema on whole body and an elevated peripheral blood eosinophil count of 5775 cells/µL at 3 months after the second HSCT. Despite prolonged treatment with systemic corticosteroids and immunomodulators the skin rash and elevated blood eosinophil count persisted. However, after 4 months of dupilumab therapy, the patient showed near-complete clearance of symptoms. The sustained clinical improvement was observed during 36 months treatment without adverse drug reactions.</p><p><strong>Conclusions: </strong>Although rare, atopic dermatitis can occur after HSCT, and dupilumab may be safe and effective for refractory conditions.</p>","PeriodicalId":51302,"journal":{"name":"Allergy Asthma and Clinical Immunology","volume":"21 1","pages":"18"},"PeriodicalIF":2.6,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12038993/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144058070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Causal role of MiRNAs in chronic rhinosinusitis: mendelian randomization and validation study.","authors":"Lei Shi, Yi-Ran Zhao, Zhi-Xuan Ma, Fu Shu","doi":"10.1186/s13223-025-00957-4","DOIUrl":"https://doi.org/10.1186/s13223-025-00957-4","url":null,"abstract":"<p><strong>Background: </strong>Despite significant advances in understanding the epigenetic landscape of chronic rhinosinusitis (CRS), the specific microRNAs (miRNAs) with a causal role in CRS pathogenesis remain unclear.</p><p><strong>Objective: </strong>This study aims to identify miRNAs that causally contribute to CRS and to elucidate their clinical relevance and underlying molecular mechanisms.</p><p><strong>Methods: </strong>We employed Mendelian randomization (MR) analysis, leveraging mirQTLs as exposure variables and two independent CRS datasets as outcomes, to identify miRNAs causally linked to CRS. Robustness of the findings was ensured through multiple sensitivity analyses. The expression levels of identified CRS-associated miRNAs were validated using qRT-PCR, and their diagnostic potential was assessed through ROC curve analysis. Target genes and potential pathways regulated by the causal miRNAs were predicted via MiRNet and enrichment analyses, followed by experimental validation using western blotting and immunohistochemistry.</p><p><strong>Results: </strong>MiR-130a-3p and miR-196b-5p were significantly associated with an increased risk of CRS, while miR-339-3p was associated with a decreased risk. These associations were confirmed by qRT-PCR, and no evidence of pleiotropy or heterogeneity was observed. ROC analysis revealed diagnostic potential for these miRNAs in CRS. Enrichment and experimental analyses suggested that the MAPK and PI3K-AKT pathways are predominantly activated by the target genes of the positively and negatively associated miRNAs, respectively.</p><p><strong>Conclusions: </strong>MiR-130a-3p and miR-196b-5p are positively associated with CRS risk, whereas miR-339-3p is protective. These miRNAs represent promising diagnostic biomarkers and therapeutic targets for CRS. The MAPK and PI3K-AKT pathways likely mediate the effects of these causal miRNAs, offering further insight into the molecular mechanisms underlying CRS.</p>","PeriodicalId":51302,"journal":{"name":"Allergy Asthma and Clinical Immunology","volume":"21 1","pages":"17"},"PeriodicalIF":2.6,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12007379/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144057317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medication-related perceptions of children and adolescents with severe asthma and moderate-to-severe atopic dermatitis: a non-interventional exploratory study.","authors":"Markus Herzig, Maike Vom Hove, Astrid Bertsche, Tobias Lipek, Wieland Kiess, Thilo Bertsche, Freerk Prenzel, Martina Patrizia Neininger","doi":"10.1186/s13223-025-00961-8","DOIUrl":"10.1186/s13223-025-00961-8","url":null,"abstract":"<p><strong>Background: </strong>Severe asthma and moderate-to-severe atopic dermatitis can significantly impact the lives of children and adolescents. However, real-world data on pediatric patients' perceptions of their medication are limited.</p><p><strong>Methods: </strong>This non-interventional cross-sectional study at a university hospital explored patients' perceptions. We included patients aged between 6 and 17 with severe asthma and/or moderate-to-severe atopic dermatitis. For patients treated with dupilumab, a minimum dupilumab treatment duration of 16 weeks was required. We conducted one structured interview per patient, based on a questionnaire consisting of open questions and ratings on 6-point Likert scales (response scale range: \"0: not at all\" to \"5: very strongly\").</p><p><strong>Results: </strong>The study included 57 participants (severe asthma: n = 31; moderate-to-severe atopic dermatitis: n = 21; both: n = 5) who reported a \"rather moderate\" burden of asthma (median: 2; Q25/Q75: 0.3/2.8) or atopic dermatitis (3; 1.5/3.5). They experienced their current medications as \"rather helpful\" (asthma: 4; 3/5; atopic dermatitis: 4; 3/5). Twelve of the participants (21%) reported refusing to take their medication because of reluctance, but all resumed treatment. All participants receiving dupilumab therapy (n = 16) reported an improvement in their disease within a maximum of 2.5 months after starting treatment. The median fear of injection decreased from 3 (0/5) before the first injection to 0.5 (0/1) at the time of the survey.</p><p><strong>Conclusions: </strong>In this real-world, interview-based study, we found that pediatric patients perceived treatment as highly beneficial for asthma and atopic dermatitis. Furthermore, pediatric patients seemed to respond well to dupilumab therapy in terms of both disease improvement and less fear of injection.</p><p><strong>Trial registration: </strong>DRKSID DRKS00028092.</p>","PeriodicalId":51302,"journal":{"name":"Allergy Asthma and Clinical Immunology","volume":"21 1","pages":"16"},"PeriodicalIF":2.6,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11978019/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143804734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks.","authors":"Stephen D Betschel, Teresa Caballero, Douglas H Jones, Hilary J Longhurst, Michael Manning, Sally van Kooten, Markus Heckmann, Sherry Danese, Ledia Goga, Autumn Ford Burnette","doi":"10.1186/s13223-025-00960-9","DOIUrl":"10.1186/s13223-025-00960-9","url":null,"abstract":"","PeriodicalId":51302,"journal":{"name":"Allergy Asthma and Clinical Immunology","volume":"21 1","pages":"15"},"PeriodicalIF":2.6,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11978150/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143804731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}